BioCentury | Jun 3, 2020
Politics, Policy & Law

Biopharma community joins call for solidarity, denounces systemic racism

The biopharma industry stood up to be counted, with top pharmas, biotechs and VCs issuing public statements of solidarity as protests in the wake of George Floyd’s death continued Tuesday. The CEOs and other leaders...
BioCentury | May 28, 2020
Product Development

May 27 Quick Takes: EC approves Zeposia in RRMS; plus Dupixent approved in children, La Jolla, Shionogi, Alnylam and Bold

EC approves Zeposia ozanimod for relapsing-remitting MS  The European Commission approved Zeposia ozanimod from Bristol Myers Squibb Co. (NYSE:BMY) to treat relapsing-remitting multiple sclerosis (RRMS). FDA approved the S1P receptor modulator in March for relapsing...
BioCentury | May 27, 2020
Deals

Sanofi's sale of Regeneron stake for $11B could set stage for both companies' growth through M&A

More than 16 years and five product launches after closing its first deal with Regeneron, Sanofi has sold its holding of roughly 20% of the biotech's shares for about $11.1 billion. While the French pharma...
BioCentury | May 16, 2020
Politics, Policy & Law

New BIO leader McMurry-Heath to focus on patients and innovation

BIO is looking to its new CEO and President, Michelle McMurry-Heath, to serve as a new face and voice for the industry, and to refocus the organization on patients and on creating the innovations they...
BioCentury | May 6, 2020
Product Development

With time at a premium, Alnylam’s siRNA strategy against COVID-19 could give it an advantage

Alnylam’s siRNA approach to treating COVID-19 will test the idea that the technology can compete with, and potentially upstage, small molecules and antibodies when it comes to development timelines. At a minimum, the “front end”...
BioCentury | May 5, 2020
Product Development

Vir, Alnylam look to year-end to start trials of siRNA product for COVID-19

Vir and Alnylam are planning to begin clinical trials for their antiviral siRNA candidate around year-end. But because the compound will be Alnylam’s first inhaled oligo to enter the clinic, it may face different regulatory...
BioCentury | Apr 17, 2020
Product Development

Vir’s dose response, safety data spur combo studies of Alnylam-partnered HBV therapy

With an eye towards a functional cure for chronic HBV, Vir plans to begin testing its siRNA therapy next half in combination with immune boosters. Phase I/II data unveiled Wednesday showed that VIR-2218 alone led...
BioCentury | Apr 14, 2020
Finance

Blackstone makes largest-ever life sciences investment in Alnylam

Blackstone’s $2 billion investment in Alnylam is a departure from its other life sciences investments in size and scope, but the deal still fits the investor’s core model of focusing on products rather than companies....
BioCentury | Apr 7, 2020
Product Development

April 6 Quick Takes: Second anemia approval for BMS, Acceleron therapy; plus EU approves trio of metabolic disease drugs, Dicerna-Alnylam and Axsome

Reblozyl gets second approval  FDA approved Reblozyl luspatercept-aamt from Bristol Myers Squibb Co. (NYSE:BMY) and Acceleron Pharma Inc. (NASDAQ:XLRN) to treat anemia in certain patients with myelodysplastic syndromes. It is the second indication for the...
BioCentury | Apr 6, 2020
Deals

Vir speeding COVID-19 mAbs into Phase II with $250M GSK investment

A $250 million investment by GlaxoSmithKline will put the clinical trial expertise and regulatory acumen of one of the leading anti-infective drug companies behind Vir’s effort to bring an antibody therapy to fight against COVID-19,...
Items per page:
1 - 10 of 959
BioCentury | Jun 3, 2020
Politics, Policy & Law

Biopharma community joins call for solidarity, denounces systemic racism

The biopharma industry stood up to be counted, with top pharmas, biotechs and VCs issuing public statements of solidarity as protests in the wake of George Floyd’s death continued Tuesday. The CEOs and other leaders...
BioCentury | May 28, 2020
Product Development

May 27 Quick Takes: EC approves Zeposia in RRMS; plus Dupixent approved in children, La Jolla, Shionogi, Alnylam and Bold

EC approves Zeposia ozanimod for relapsing-remitting MS  The European Commission approved Zeposia ozanimod from Bristol Myers Squibb Co. (NYSE:BMY) to treat relapsing-remitting multiple sclerosis (RRMS). FDA approved the S1P receptor modulator in March for relapsing...
BioCentury | May 27, 2020
Deals

Sanofi's sale of Regeneron stake for $11B could set stage for both companies' growth through M&A

More than 16 years and five product launches after closing its first deal with Regeneron, Sanofi has sold its holding of roughly 20% of the biotech's shares for about $11.1 billion. While the French pharma...
BioCentury | May 16, 2020
Politics, Policy & Law

New BIO leader McMurry-Heath to focus on patients and innovation

BIO is looking to its new CEO and President, Michelle McMurry-Heath, to serve as a new face and voice for the industry, and to refocus the organization on patients and on creating the innovations they...
BioCentury | May 6, 2020
Product Development

With time at a premium, Alnylam’s siRNA strategy against COVID-19 could give it an advantage

Alnylam’s siRNA approach to treating COVID-19 will test the idea that the technology can compete with, and potentially upstage, small molecules and antibodies when it comes to development timelines. At a minimum, the “front end”...
BioCentury | May 5, 2020
Product Development

Vir, Alnylam look to year-end to start trials of siRNA product for COVID-19

Vir and Alnylam are planning to begin clinical trials for their antiviral siRNA candidate around year-end. But because the compound will be Alnylam’s first inhaled oligo to enter the clinic, it may face different regulatory...
BioCentury | Apr 17, 2020
Product Development

Vir’s dose response, safety data spur combo studies of Alnylam-partnered HBV therapy

With an eye towards a functional cure for chronic HBV, Vir plans to begin testing its siRNA therapy next half in combination with immune boosters. Phase I/II data unveiled Wednesday showed that VIR-2218 alone led...
BioCentury | Apr 14, 2020
Finance

Blackstone makes largest-ever life sciences investment in Alnylam

Blackstone’s $2 billion investment in Alnylam is a departure from its other life sciences investments in size and scope, but the deal still fits the investor’s core model of focusing on products rather than companies....
BioCentury | Apr 7, 2020
Product Development

April 6 Quick Takes: Second anemia approval for BMS, Acceleron therapy; plus EU approves trio of metabolic disease drugs, Dicerna-Alnylam and Axsome

Reblozyl gets second approval  FDA approved Reblozyl luspatercept-aamt from Bristol Myers Squibb Co. (NYSE:BMY) and Acceleron Pharma Inc. (NASDAQ:XLRN) to treat anemia in certain patients with myelodysplastic syndromes. It is the second indication for the...
BioCentury | Apr 6, 2020
Deals

Vir speeding COVID-19 mAbs into Phase II with $250M GSK investment

A $250 million investment by GlaxoSmithKline will put the clinical trial expertise and regulatory acumen of one of the leading anti-infective drug companies behind Vir’s effort to bring an antibody therapy to fight against COVID-19,...
Items per page:
1 - 10 of 959